ABVC BioPharma, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 0.006109 million compared to USD 0.31286 million a year ago. Net loss was USD 2.26 million compared to USD 1.86 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to USD 0.59 a year ago. Diluted loss per share from continuing operations was USD 0.68 compared to USD 0.59 a year ago.
For the six months, sales was USD 0.134381 million compared to USD 0.33852 million a year ago. Net loss was USD 4.09 million compared to USD 7.85 million a year ago. Basic loss per share from continuing operations was USD 1.24 compared to USD 2.65 a year ago. Diluted loss per share from continuing operations was USD 1.24 compared to USD 2.65 a year ago.